Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock
Incyte Corporation (Nasdaq: INCY) (the “Company”) today announced that the Company intends to offer to sell, subject to market
and other conditions, 4,945,000 shares of its common stock in an underwritten public offering. In connection with the offering, the
Company expects to grant the underwriter an option to purchase up to an additional 741,750 shares on the same terms and
conditions.
The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research
and development activities, capital expenditures and potential strategic transactions.
BofA Merrill Lynch is acting as the sole underwriter of this offering.
The shares will be issued pursuant to an effective shelf registration statement. Before you invest, you should read the
prospectus included in that registration statement and the documents incorporated by reference in that registration statement as
well as the prospectus supplement related to the offering. You may obtain these documents free of charge by visiting EDGAR on the
SEC website at www.sec.gov. Printed copies of the preliminary prospectus supplement and prospectus relating to the offering may
be obtained, when available, from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001,
Attn: Prospectus Department or by email at dg.prospectus_requests@baml.com.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s
common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any state. Any offer, if at all, will be
made only by means of a prospectus, including a prospectus supplement, forming a part of the effective shelf registration
statement.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements with
respect to the proposed public offering of common stock, expectations with respect to granting the underwriter an option to
purchase additional shares and the intended use of net proceeds from the offering, are all forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements
are subject to risks and uncertainties that may cause actual results to differ materially, including those related to completion of
the public offering on the anticipated terms or at all, market conditions, satisfaction of the conditions to closing of the
proposed offering, risks relating to our dependence upon our revenues from JAKAFI, cash requirements arising from the development
of new products by us and our current and potential collaborators, the risk of significant delays or costs in obtaining regulatory
approvals, risks relating to our collaborators’ ability to develop and commercialize drug candidates, and cash requirements arising
from our business development activities, the fact that Incyte management will have broad discretion in the use of the proceeds
from any sale of the shares, and other risks detailed from time to time in Incyte’s filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Incyte disclaims any intent or
obligation to update these forward-looking statements.
Incyte Corporation
David W. Gryska, +1-302-498-6700
dgryska@incyte.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907006713/en/